新力金融(600318.SH):上半年淨利潤1815.93萬元,同比下降23.42%
格隆匯8月15日丨新力金融(600318.SH)公佈2024年半年度報吿,報吿期實現營業收入1.56億元,同比下降11.93%;歸屬於上市公司股東的淨利潤1815.93萬元,同比下降23.42%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1703.49萬元,同比下降23.64%;基本每股收益0.0354元。
公司歸屬於上市公司股東淨利潤下降的主要影響因素有:1.融資租賃板塊整體收入略降,典當公司綜合服務費收入下降較大,小額貸款板塊收入略增、手付通公司營業收入同比基本持平,公司收入同比下降11.93%。2.上年同期子公司清收效果較好,部分項目信用減值損失實現轉回。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.